Concord Biotech Limited (NSE:CONCORDBIO)
India · Delayed Price · Currency is INR | Market Cap | 128.60B -19.3% |
| Revenue (ttm) | 11.08B -6.7% |
| Net Income | 2.75B -22.7% |
| EPS | 26.24 -22.9% |
| Shares Out | 104.62M |
| PE Ratio | 46.86 |
| Forward PE | 34.97 |
| Dividend | 7.55 (0.61%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 96,681 |
| Open | 1,270.50 |
| Previous Close | 1,270.70 |
| Day's Range | 1,212.50 - 1,279.70 |
| 52-Week Range | 987.00 - 1,615.00 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 1,552.60 (+26.3%) |
| Earnings Date | Oct 28, 2026 |
About Concord Biotech
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for ... [Read more]
Financial Performance
In fiscal year 2026, Concord Biotech's revenue was 10.55 billion, a decrease of -12.10% compared to the previous year's 12.00 billion. Earnings were 2.61 billion, a decrease of -29.80%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CONCORDBIO stock is "Buy." The 12-month stock price target is ₹1,553, which is an increase of 26.30% from the latest price.
News
Concord Biotech Transcript: Q1 26/27
Q1 FY 2027 saw 26% revenue growth, led by APIs and strong export performance, with gross margin at 78.9% and EBITDA margin at 32%. Management expects growth to exceed historical rates, driven by a robust pipeline, new launches, and ramp-up of injectables and Stellon Biotech.
Concord Biotech Quarterly report: Q1 2027
Concord Biotech has published its Q1 2027 quarterly earnings report on August 3, 2026.
Concord Biotech Slides: Q1 2027
Concord Biotech has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 3, 2026.
Concord Biotech Transcript: Q4 25/26
FY 2026 saw a 12% revenue decline due to geopolitical and supply chain disruptions, but profitability remained resilient with a 35% EBITDA margin. Management expects FY 2027 growth to exceed historical rates, supported by new facilities, regulatory approvals, and operating leverage.
Concord Biotech Quarterly report: Q4 2026
Concord Biotech has published its Q4 2026 quarterly earnings report on June 1, 2026.
Concord Biotech Slides: Q4 2026
Concord Biotech has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 1, 2026.
Concord Biotech Annual report: Q4 2026
Concord Biotech has published its Q4 2026 annual report on June 1, 2026.
Concord Biotech Transcript: Q3 25/26
Q3 FY26 saw 14% revenue growth year-over-year, with API volumes driving performance and injectables poised for future growth. Margins were impacted by startup costs, but normalization is expected as new facilities scale. Cash position remains strong, supporting both organic and inorganic expansion.
Concord Biotech Quarterly report: Q3 2026
Concord Biotech has published its Q3 2026 quarterly earnings report on February 12, 2026.
Concord Biotech Slides: Q3 2026
Concord Biotech has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 12, 2026.
Concord Biotech Transcript: Q2 25/26
Revenue declined 20% YoY in Q2 FY2026 due to regulatory and geopolitical delays, but management expects a strong H2 as deferred sales resume and new facilities ramp up. EBITDA margin, adjusted for startup costs, remained robust at 41%.
Concord Biotech Quarterly report: Q2 2026
Concord Biotech has published its Q2 2026 quarterly earnings report on November 14, 2025.
Concord Biotech Slides: Q2 2026
Concord Biotech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 14, 2025.